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ABSTRACT 
A non-synonymous genetic rare variant, rs75932628-T (p.R47H), in the TREM2 
gene has recently been reported to be a strong genetic risk factor for Alzheimer's disease 
(AD). Also, rare recessive mutations have been associated with frontotemporal 
dementia (FTD). We aimed to investigate the role of p.R47H variant in AD and FTD 
through a multi-center study comprising 3,172 AD and 682 FTD patients and 2,169 
healthy controls from Spain. We found that 0.6% of AD cases carried this variant 
compared to 0.1% of controls (odds ratio [OR]=4.12, 95% confidence interval [CI]: 
1.21-14.00, P=0.014). A meta-analysis comprising 32,598 subjects from four previous 
studies demonstrated the large effect of the p.R47H variant in AD risk (OR=4.11, 95% 
CI: 2.99-5.68, P=5.27x10-18). We did not find an association between p.R47H and age 
of onset of AD or family history of dementia. Finally, none of the FTD patients 
harbored this genetic variant. These data strongly support the important role of p.R47H 
in AD risk and suggest that this rare genetic variant is not related to FTD. 
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1. Introduction 
The rapid population growth in recent centuries and the evolutionary forces that 
shape allelic variation over time have led to a large number of rare genetic variants in 
the human genome, and they seem to vastly exceed the number of common alleles 
(Tennessen et al. 2012). A substantial fraction of these rare variants may have 
functional consequences and therefore can contribute to the allelic architecture of 
complex diseases (Pritchard, 2001). A very recent example of a rare genetic variant with 
large individual effect is the non-synonymous amino acid substitution p.R47H 
(rs75932628) in the gene encoding the triggering receptor expressed on myeloid cells 2 
(TREM2) and its association with the risk for sporadic Alzheimer's disease (AD) 
(Guerreiro et al. 2013; Jonsson et al. 2013). This association has also been replicated in 
a cohort of French patients with an early-onset form of AD (EOAD, age of onset ≤65 
years) (Pottier et al. 2013), and in a Spanish study with a series of patients that 
comprised both late and EOAD (Benitez et al. 2013). Interestingly, homozygous 
mutations in TREM2 have been described in patients with an unusual early-onset 
frontotemporal dementia (FTD) from consanguineous families living in the Anatolian 
region of Turkey (Guerreiro et al. 2013) and in a Colombian family (Giraldo et al. 
2013), thus broadening the clinical heterogeneity spectrum caused by mutations in this 
particular locus. In addition, homozygous mutations in TREM2 are also the cause of 
Nasu-Hakola disease, which is mainly characterized by pre-senile FTD and cystic bone 
lesions (Paloneva et al. 2002). 
Since (i) the TREM2 p.R47H variant has been related to the broad spectrum of 
AD, including EOAD, (ii) no specific assessment of this variant has been performed in 
FTD, and (iii) allele frequency of the p.R47H varies across populations, we aimed to 
evaluate how this non-synonymous amino acid change contributes to the risk of early- 
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and late-onset forms of AD or FTD by studying a large cohort of patients and controls 
from Spanish origin.  
 
2. Methods 
2.1. Study subjects 
A total of 3,172 AD patients (mean age at onset 74.8 ± 9.9 years, 68.5% 
women), 682 FTD patients (mean age at onset 64.8 ± 9.9 years, 46.8% women), and 
2,169 healthy controls (mean age at clinical assessment 75.4 ± 10.3 years, 58.2% 
women) were collected through a collaborative effort involving 11 specialized centers 
across the country. All individuals were Spanish and of European origin. Among AD 
patients, 466 were classified as early-onset cases (EOAD) (cut-off age of onset being 65 
years). Patients were diagnosed using established clinical criteria for AD (McKhann et 
al. 1984) or FTD (Neary et al. 1998). All participants or their families provided written 
informed consent, and the study was approved by the respective ethics committees. 
 
2.2. Genotyping 
Genotyping of the rs75932628 (p.R47H) variant was performed using three 
approaches: TaqMan SNP Genotyping Assays (Applied Biosystems, Foster city, 
California), High Resolution Melting (Eco-PCR, Illumina, San Diego, California), and 
KASPar (KBioscience, Berlin). A human DNA sample carrying a T-allele (rs75932628-
T) in heterozygous state was distributed to all genotyping centers and was included as a 





2.3. Statistical analysis 
Genotype frequency comparisons were performed by Fisher's exact test. 
Differences between groups were analyzed by Student's t-test for continuous data. 
Multiple logistic regression models were used to adjust for covariates, such as age, 
gender and APOE-ε4 status. Data were analyzed using the Statistical Package for the 
Social Sciences, version 19.0.0 (SPSS Inc., Chicago, IL). Genetic interactions 
(epistasis) were assessed by the synergy factor analysis (Cortina-Borja et al. 2009). 
Meta-analysis was conducted using the inverse variance method (fixed effects model) in 
Episheet excel application according to Fleiss (Fleiss 1993). Fixed and random effects 
meta-analyses were automatically generated by Episheet. The weighting of each study 
was calculated using the estimated standard errors. The bona fide genome-wide 
significant P-value threshold was established at P<5x10-8 (de Bakker et al. 2008). Final 
meta-analysis results and Forest plot for TREM2 p.R47H showing association results in 
all available data were derived using OpenMeta (Wallace et al. 2009). Power 
calculations were performed with the PS software (Version 2.1.30). 
 
3. Results 
 A total of 6,023 individuals were genotyped for the p.R47H polymorphism, and 
distribution of genotype frequencies across phenotypes is presented in Table 1. The T 
allele at the rs75932628 biallelic polymorphism was carried by 0.6% of AD cases and 
0.1% of controls (P=0.014), and yielded an odds ratio (OR) of 4.12 [95% confidence 
interval [CI]: 1.21-14.00], almost identical to the risk conferred by the APOE-ε4 allele 
(4.2, Table 1). Although not statistically significant, age at onset of AD was slightly 
lower in rs75932628-T carriers than noncarriers (70±6.0 and 74.8±9.9 years, 
respectively, P=0.08). To effectively detect whether the association between 
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rs75932628-T variant and AD was modified by age, the sample was stratified into 
EOAD cases (age of onset ≤65 years old, n=466) and late-onset cases (>65 years old, 
n=2,375). The rs75932628-T association was replicated within the late-onset AD series 
(OR=4.28; 95% CI: 1.23-14.92, P=0.014). However, no significant association was 
found for the EOAD series (OR=3.12; 95% CI: 0.52-18.68, P=0.217). Data regarding 
family history of dementia were available for 14/18 AD patients carrying the 
rs75932628-T allele. Of these patients, only five (35.7%) reported a positive family 
history of dementia. This percentage was almost identical to the prevalence of family 
history of dementia in rs75932628-T noncarriers (35.3%, P=0.974). To further address 
the association between the p.R47H variant and the risk of AD, and to compare the 
observed effect size of p.R47H among different populations, we conducted a meta-
analysis using our data and the available data from the literature (Benitez et al. 2013; 
Guerreiro et al. 2013; Jonsson et al. 2013; Pottier et al. 2013). In total, we analyzed the 
genotypes of 32,598 subjects comprising 12,967 patients and 19,631 controls. The 
summary OR under a fixed effect model showed that individuals with the p.R47H 
variant were 4.11 times more likely to develop AD than noncarriers (95% CI: 2.99-5.68, 
P=5.27x10-18, Figure 1). No evidence of heterogeneity between studies was detected 
(Q=2.17, P>0.98 with nine degrees of freedom). 
We next assessed the effect of the APOE- ε4 allele on the association between 
rs75932628-T and the risk of AD. The risk of the p.R47H variant was no longer 
significant after adjustment for the APOE- ε4 allele (P=0.34). Since there were 
significant differences between the frequency of rs75932628-T in carriers of the APOE-
ε4 allele compared to noncarriers (P=0.007), we then evaluated whether the TREM2 
association was indeed confounded by the presence of APOE- ε4 in rs75932628-T 
carriers through a meta-analysis that included two previous studies with six populations 
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(Jonsson et al. 2013; Pottier et al. 2013). This analysis showed no difference in the 
frequency of rs75932628-T carriers according to APOE- ε4 status (P=0.28, Suppl. Fig. 
1). No significant interaction between APOE- ε4 and rs75932628-T resulted from the 
logistic-regression model (P=0.577). Evaluation of this interaction by the synergy factor 
(SF) analysis, which measures both the size and significance of genetic interactions 
(Cortina-Borja et al. 2009), corroborated the lack of synergy between APOE- ε4 and 
rs75932628-T (SF=1.31, P=0.43).  
 The study of the p.R47H variant in the FTD group (n=682) did not disclose any 
carrier of this genetic variant.  
 
4. Discussion 
 The role of rare genetic variants in common disorders has been fueled in the last 
few years by the appearance of next-generation sequencing technologies. Two 
independent works have recently demonstrated the power of these techniques. After a 
large scale analysis of sequencing data, they identified the rare p.R47H substitution as a 
major genetic risk factor for AD (Guerreiro et al. 2013; Jonsson et al. 2013). In the 
present work we were able to replicate this finding by analyzing a large case-control 
cohort comprising more than 6,000 individuals. The effect size of the TREM2 
rs75932628-T rare variant was consistent with those reported previously (Guerreiro et 
al. 2013; Jonsson et al. 2013; Benitez et al. 2013), and reached the same magnitude as the 
APOE-ε4 allele, the most important genetic risk factor for AD. Our meta-analysis 
comprising > 32,000 subjects strongly supports the important role of the p.R47H non-
synonymous variant in AD risk. 
We were not able to replicate the recently reported association of rs75932628-T 
and EOAD risk in a French population (Pottier et al. 2013), despite the frequency of 
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EOAD patients carrying the p.R47H variant being slightly higher than controls (0.4% 
and 0.1%, respectively). A possible explanation for this lack of replication is that the 
frequency of the rs75932628-T variant in the Spanish population is much lower than 
that of the French population (0.14% and 0.5%, respectively in controls, 0.4% and 2.0% 
in patients). Therefore, even though our sample size was almost double that of Pottier et 
al., the much lower frequency of the rs75932628-T in our population could have led to 
an insufficient statistical power. The present study had a power of 46% (alpha=0.05) to 
detect a risk equal to that reported in the French analysis. It is important to note, 
however, that patients carrying the rs75932628-T variant had a slightly, although not 
significantly, earlier age of onset, thus raising the question as to whether this genetic 
variant could modulate the age of AD onset. 
We did not find any interaction between the ε4 allele of the APOE gene and the 
p.R47H variant. Nevertheless, the APOE-ε4 adjusted risk of the rs75932628-T variant 
resulted in a loss of statistical significance. The high prevalence of the APOE-E4 
isoform in AD patients, in conjunction with its prominent effect on AD risk may explain 
this somewhat unexpected outcome. However, our meta-analysis to evaluate the effect 
of APOE- ε4 on the association of rs75932628-T with AD strongly indicates the 
independence of both genes in the risk of AD. Therefore, co-occurrence of both alleles 
(rs75932628-T and APOE- ε4) in our AD series was not confirmed in other populations 
and might be due to random effects. 
As far as we know, this is the first study to assess the role of the p.R47H variant 
in FTD patients. Our results strongly suggest that being a heterozygous carrier of this 
variant does not contribute to the risk of common forms of FTD and emphasize the 
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Figure 1:  




Suppl. Figure 1: 
Forest plot showing the effect of the APOE-ε4 allele on the association of p.R47H 
variant with Alzheimer's disease in different populations and overall OR comparing 
APOE- ε 4 carriers and non-carriers. 
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Table 1. Frequency of TREM2 p.R47H and APOE-ε4 carriers across phenotypes. 
 TREM2 p.R47H 
N (frequency %) 
APOE-ε4 
N (frequency %) 
Controls 3 (0.14) 257 (16.1) 
AD 18 (0.57) 1,264 (44.8) 
FTD  - 64 (24.5) 
OR [95%CI] (AD vs C)  4.12 [1.21-14.00], P = 0.014 4.23 [3.61-4.93], P = 6.9x10-83
OR [95%CI] (FTD vs C) -, P = 1 1.69 [1.24-2.31], P = 0.001 
 
 
 
